Eylea Description

The solution is a clear to slightly opalescent, colourless to pale yellow and iso-osmotic solution.
40 mg/mL vial: 1 mL solution for intravitreal injection contains 40 mg aflibercept.
One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.
114.3mg/mL vial: pH 5.8.
1 ml solution for injection contains 114.3 mg aflibercept*.
Each vial contains 30.1 mg aflibercept in 0.263 ml solution. This provides a usable amount to deliver a single dose of 0.07 ml containing 8 mg aflibercept.
* Aflibercept is a fusion protein consisting of portions of human VEGF (vascular endothelial growth factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
Pre-filled syringe: 1 mL solution for injection contains 40 mg aflibercept*.
One pre-filled syringe contains an extractable volume of at least 0.09 mL, equivalent to at least 3.6 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.
*Fusion protein consisting of portions of human VEGF (Vascular Endothelial Growth Factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
Excipients/Inactive Ingredients: Polysorbate 20 (E 432), Monohydrate sodium dihydrogen phosphate (for pH adjustment), Heptahydrate disodium hydrogen phosphate (for pH adjustment), Sodium chloride, Sucrose, Water for injections.
114.3mg/mL vial: L-arginine monohydrochloride, L-histidine monohydrochloride monohydrate, L-histidine.